Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRTX NASDAQ:LSTA NASDAQ:MYNZ NASDAQ:SCYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRTXGalera Therapeutics$0.10+4.8%$0.08$0.02▼$0.15$7.91M2.64216,730 shs10,008 shsLSTALisata Therapeutics$3.24+1.2%$4.00$1.81▼$5.07$29.51M0.81131,785 shs73,005 shsMYNZMainz Biomed$3.47+4.2%$0.97$0.55▼$4.43$31.44M0.31371,589 shs8.30 million shsSCYXSCYNEXIS$0.71+4.8%$0.90$0.57▼$1.31$32.11M1.12513,881 shs623,122 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRTXGalera Therapeutics-0.10%-0.89%0.00%+132.56%+311.52%LSTALisata Therapeutics+1.91%+2.56%0.00%-27.11%+21.21%MYNZMainz Biomed0.00%+0.91%+556.03%+438.83%+58.57%SCYXSCYNEXIS-6.88%+3.68%-33.24%-4.08%-12.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRTXGalera Therapeutics$0.10+4.8%$0.08$0.02▼$0.15$7.91M2.64216,730 shs10,008 shsLSTALisata Therapeutics$3.24+1.2%$4.00$1.81▼$5.07$29.51M0.81131,785 shs73,005 shsMYNZMainz Biomed$3.47+4.2%$0.97$0.55▼$4.43$31.44M0.31371,589 shs8.30 million shsSCYXSCYNEXIS$0.71+4.8%$0.90$0.57▼$1.31$32.11M1.12513,881 shs623,122 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRTXGalera Therapeutics-0.10%-0.89%0.00%+132.56%+311.52%LSTALisata Therapeutics+1.91%+2.56%0.00%-27.11%+21.21%MYNZMainz Biomed0.00%+0.91%+556.03%+438.83%+58.57%SCYXSCYNEXIS-6.88%+3.68%-33.24%-4.08%-12.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRTXGalera Therapeutics 0.00N/AN/AN/ALSTALisata Therapeutics 1.67Reduce$15.00363.11% UpsideMYNZMainz Biomed 1.50ReduceN/AN/ASCYXSCYNEXIS 2.00Hold$3.00320.17% UpsideCurrent Analyst Ratings BreakdownLatest GRTX, SCYX, MYNZ, and LSTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026LSTALisata Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/15/2026LSTALisata Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral4/21/2026LSTALisata Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/6/2026MYNZMainz Biomed Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/ALSTALisata Therapeutics$170K173.57N/AN/A$1.17 per share2.77MYNZMainz Biomed$659.94K47.64N/AN/A$2.61 per share1.33SCYXSCYNEXIS$20.60M1.55N/AN/A$0.92 per share0.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRTXGalera Therapeutics-$59.08M$0.64N/AN/AN/AN/AN/A-99.34%8/12/2026 (Estimated)LSTALisata Therapeutics-$16.59M-$1.86N/AN/AN/AN/A-103.54%-83.08%8/6/2026 (Estimated)MYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ASCYXSCYNEXIS-$8.61M-$0.48N/AN/AN/A-41.79%-57.16%-39.48%8/12/2026 (Estimated)Latest GRTX, SCYX, MYNZ, and LSTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026LSTALisata TherapeuticsN/A-$0.50N/A-$0.50N/AN/A5/11/2026Q1 2026SCYXSCYNEXIS-$0.10-$0.42-$0.32-$0.42$0.08 millionN/A3/12/2026Q4 2025LSTALisata Therapeutics-$0.74-$0.33+$0.41-$0.33N/A$0.10 million3/4/2026Q4 2025SCYXSCYNEXIS$0.29$0.25-$0.04$0.25$8.10 million$17.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGRTXGalera TherapeuticsN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRTXGalera TherapeuticsN/A9.749.74LSTALisata TherapeuticsN/A4.234.23MYNZMainz Biomed0.440.520.43SCYXSCYNEXISN/A3.943.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRTXGalera Therapeutics50.77%LSTALisata Therapeutics8.94%MYNZMainz BiomedN/ASCYXSCYNEXIS54.37%Insider OwnershipCompanyInsider OwnershipGRTXGalera Therapeutics12.90%LSTALisata Therapeutics9.60%MYNZMainz Biomed18.20%SCYXSCYNEXIS4.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableLSTALisata Therapeutics309.11 million8.23 millionNot OptionableMYNZMainz Biomed309.06 million7.41 millionNot OptionableSCYXSCYNEXIS6044.66 million42.49 millionOptionableGRTX, SCYX, MYNZ, and LSTA HeadlinesRecent News About These CompaniesSCYNEXIS (NASDAQ:SCYX) Shares Set to Reverse Split on Monday, June 1stMay 24 at 1:13 AM | americanbankingnews.comSCYNEXIS Announces One-for-Eight Reverse Stock SplitMay 22, 2026 | globenewswire.comAnalyzing Phio Pharmaceuticals (NASDAQ:PHIO) and SCYNEXIS (NASDAQ:SCYX)May 17, 2026 | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) Downgraded to Sell Rating by Wall Street ZenMay 16, 2026 | americanbankingnews.comSCYNEXIS (SCYX) price target increased by 20.73% to 4.28May 14, 2026 | msn.comSCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 11, 2026 | globenewswire.comSCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 6, 2026 | globenewswire.comSCYNEXIS Raises $40 Million in Strategic Private PlacementApril 19, 2026 | theglobeandmail.comSCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics TranscriptMarch 31, 2026 | seekingalpha.comSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney ...March 31, 2026 | markets.businessinsider.comWhy did SCYX stock jump 10% in pre-market today?March 31, 2026 | msn.comPoxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 MillionMarch 31, 2026 | businesswire.comSCYNEXIS Announces $40.0 Million Private PlacementMarch 31, 2026 | globenewswire.comSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)March 31, 2026 | globenewswire.comSCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal TherapyMarch 12, 2026 | insidermonkey.comScynexis: Q4 Earnings SnapshotMarch 4, 2026 | wiltonbulletin.comWSCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate UpdateMarch 4, 2026 | globenewswire.comSCYNEXIS, Inc. Initiates Phase 1 Trial for Intravenous Antifungal SCY-247 Following FDA DesignationsFebruary 26, 2026 | quiverquant.comQSCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247February 26, 2026 | globenewswire.comCERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsFebruary 17, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRTX, SCYX, MYNZ, and LSTA Company DescriptionsGalera Therapeutics NASDAQ:GRTX$0.10 +0.00 (+4.80%) As of 01:41 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Lisata Therapeutics NASDAQ:LSTA$3.24 +0.04 (+1.22%) As of 01:59 PM Eastern This is a fair market value price provided by Massive. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Mainz Biomed NASDAQ:MYNZ$3.47 +0.14 (+4.20%) As of 05/26/2026Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.SCYNEXIS NASDAQ:SCYX$0.71 +0.03 (+4.85%) As of 02:35 PM Eastern This is a fair market value price provided by Massive. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case Zscaler Stock Drops 30%: Why the Dip Is a Buy Opportunity Shake Shack Insiders Buy as SHAK Stock Faces More Pressure Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest Move Record Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy? Qualcomm's TikTok AI Chip Deal Rewrites the Rules Micron’s $1 Trillion Memory Melt-Up Keysight: The AI and Defense Stock Seeing Big Price Target Boosts Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
